MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for misleading statements regarding its Phase 3 clinical programs, potentially affecting investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].